- POAI recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY Systems
- STREAMWAY Systems are the first truly continuous, direct-to drain fluid-disposal solutions designed specifically for medical applications
- The announcement is another positive indication that POAI subsidiary Skyline Medical offers tremendous qualitative, long-term potential
In a significant announcement that bodes well for the company, Predictive Oncology Inc. (NASDAQ: POAI) announced that its Skyline Medical Division, producer of the STREAMWAY(R) System, has completed the sale of 10 systems to a major New York hospital (http://ibn.fm/dXHwp). The sale exceeds POAI’s largest single-hospital sale to date, and it is anticipated that the systems collectively will handle 6,000 procedures every year.
The revolutionary FDA-approved, CE-marked STREAMWAY System is the first truly continuous, direct-to drain, fluid-disposal system designed specifically for medical applications such as radiology, endoscopy, surgery, urology and cystoscopy procedures.
STREAMWAY is transforming the way healthcare facilities process and handle potentially infectious waste. The innovative system connects directly to a facility’s plumbing system in order to automate the collection, measurement and disposal of waste fluids. This proprietary approach minimizes human intervention, creates a safer system, and provides improved compliancy with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines (http://ibn.fm/O0FzQ).
Moreover, because the STREAMWAY system doesn’t require canisters and evacuated bottles for collection purposes, it eliminates approximately 50 million potentially disease-infected canisters that wind up in landfills around the country. In addition to the positive environmental impact, the system also reduces overhead costs.
For Predictive Oncology, this announcement represents a significant financial milestone. As POAI’s largest single-hospital transaction ever, the sale indicates the credibility and trust the STREAMWAY System is building within the industry. In addition, the sale is another positive indication that Skyline Medical, a POAI subsidiary, provides tremendous qualitative, long-term potential as it continues to focus on and develop innovative and revolutionary technology and alternatives. Through its STREAMWAY System, Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.
Predictive Oncology operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries; and second, production of the STREAMWAY System through Skyline Medical.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI